Possibilities to prevent acute exacerbation of chronic obstructive pulmonary disease using inhalational therapy. A Report of Expert Panel of...
Авдеев С. Н., Белевскиy А. С., Аисанов З. Р., Архипов В. В., Лешченко И. В., Овчаренко С. И., Синопал'ников А. И., Визел А. А., Емел'янов А. В., Жестков А. В., Зyков К. А., Кузубова Н. А., Прозорова Г. Г., Черняк Б. А., Шапорова Н. Л., Шмелев Е. И.
Пульмонология
Т. 28, Вып. 3, С. 368-380
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.18093/0869-0189-2018-28-3-368-380
Аннотация:
An impact of acute exacerbation of COPD (AECOPD) on the course and the prognosis of chronic obstructive pulmonary disease depends on severity of the exacerbation. Moderate and severe exacerbations are considered as clinically significant events. Clinical studies investigating a role of inhalational therapy for the risk of AECOPD differed significantly in important parameters and the patients involved were not fully described in the real clinical practice. Tiotropium alone did not demonstrate any benefit over other inhalational therapies, such as inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations and long-acting muscarinic antagonist (LAMA)/LABA combinations, for risk reduction of moderate to severe exacerbations. A benefit of tiotropium/olodaterol combination over tiotropium for the reduction of risk of clinically significant exacerbations was first shown in DYNAGITO study; patients' groups in this study did not differ in a rate and a spectrum of adverse events inclu
Ключевые слова:
Chronic obstructive pulmonary disease; Exacerbations; Inhalational therapy; Inhaled corticosteroids; Long-acting bronchodilators; Prevention; Tiotropium; Tiotropium/olodaterol
beta 2 adrenergic receptor stimulating agent; bronchodilating agent; corticosteroid; long acting drug; muscarinic receptor blocking agent; olodaterol plus tiotropium bromide; tiotropium bromide; adverse event; Article; cardiovascular disease; chronic obstructive lung disease; clinical practice; disease course; disease exacerbation; disease severity; dyspnea; human; medical society; risk reduction; treatment outcome
Язык текста: Русский
ISSN: 0869-0189
Авдеев С. Н. Сергей Николаевич 1968-
Белевскиy А. С.
Аисанов З. Р.
Архипов В. В.
Лешченко И. В.
Овчаренко С. И. Светлана Ивановна 1937-
Синопал'ников А. И.
Визел А. А.
Емел'янов А. В.
Жестков А. В.
Зyков К. А.
Кузубова Н. А.
Прозорова Г. Г.
Черняк Б. А.
Шапорова Н. Л.
Шмелев Е. И.
Avdeev S. N. Sergej Nikolaevich 1968-
Belevskiy A. S.
Aisanov Z. R.
Arkhipov V. V.
Leshchenko I. V.
Ovcharenko S. I. Svetlana Ivanovna 1937-
Sinopal'nikov A. I.
Vizel A. A.
Emel'yanov A. V.
Zhestkov A. V.
Zykov K. A.
Kuzubova N. A.
Prozorova G. G.
Chernyak B. A.
Shaporova N. L.
Shmelev E. I.
Possibilities to prevent acute exacerbation of chronic obstructive pulmonary disease using inhalational therapy. A Report of Expert Panel of Russian Respiratory Society
Possibilities to prevent acute exacerbation of chronic obstructive pulmonary disease using inhalational therapy. A Report of Expert Panel of...
Текст визуальный непосредственный
Пульмонология
Научно-практический журнал "Пульмонология"
Т. 28, Вып. 3 С. 368-380
2018
Статья
Chronic obstructive pulmonary disease Exacerbations Inhalational therapy Inhaled corticosteroids Long-acting bronchodilators Prevention Tiotropium Tiotropium/olodaterol
beta 2 adrenergic receptor stimulating agent bronchodilating agent corticosteroid long acting drug muscarinic receptor blocking agent olodaterol plus tiotropium bromide tiotropium bromide adverse event Article cardiovascular disease chronic obstructive lung disease clinical practice disease course disease exacerbation disease severity dyspnea human medical society risk reduction treatment outcome
An impact of acute exacerbation of COPD (AECOPD) on the course and the prognosis of chronic obstructive pulmonary disease depends on severity of the exacerbation. Moderate and severe exacerbations are considered as clinically significant events. Clinical studies investigating a role of inhalational therapy for the risk of AECOPD differed significantly in important parameters and the patients involved were not fully described in the real clinical practice. Tiotropium alone did not demonstrate any benefit over other inhalational therapies, such as inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combinations and long-acting muscarinic antagonist (LAMA)/LABA combinations, for risk reduction of moderate to severe exacerbations. A benefit of tiotropium/olodaterol combination over tiotropium for the reduction of risk of clinically significant exacerbations was first shown in DYNAGITO study; patients' groups in this study did not differ in a rate and a spectrum of adverse events inclu